Baxter International Inc. announced Tuesday that it has obtained exclusive rights to a new respiratory drug called Glassia, which treats a hereditary disease called AATD, or alpha-1 antitrypsin deficiency, that may lead to emphysema. Get the full story »
Inside these posts: AATD
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
